OptimizeRx delivered a strong fourth quarter with record net income and adjusted EBITDA, despite flat year-over-year revenue. The company successfully achieved 'Rule of 40' status for the full year 2025 and authorized a new $10 million share repurchase program.

OptimizeRx delivered a robust second quarter in 2025, with revenue increasing by 55% year-over-year to $29.2 million and gross profit rising by 59% to $18.6 million. The company achieved GAAP net income of $1.5 million and non-GAAP net income of $4.5 million, demonstrating a significant turnaround from a net loss in the prior year. OptimizeRx also strengthened its financial position by paying down $4.5 million of principal on its outstanding term loan and raised its full-year 2025 guidance for both revenue and adjusted EBITDA.

OptimizeRx delivered top-line growth and improved bottom-line performance in Q1 2025, supported by enhanced gross profit and positive non-GAAP earnings, alongside raised full-year guidance.

OptimizeRx reported Q4 2024 revenue of $32.3 million, up 14% year-over-year, driven by increased demand for its healthcare technology solutions. The company achieved a gross profit of $22.0 million, reflecting a gross margin of 68%. While GAAP net income was nearly breakeven at -$0.1 million, non-GAAP net income totaled $5.5 million. Adjusted EBITDA surged by 53% to $8.8 million, highlighting operational efficiencies.

OptimizeRx reported Q3 2024 financial results with revenue of $21.3 million, a 30% increase year-over-year. The company's gross profit increased by 37% to $13.4 million, with a gross margin of 63%. They also won 5 DAAP deals during the quarter and paid down $2.0 million of their term loan.

OptimizeRx reported Q2 2024 revenue of $18.8 million, a 36% increase year-over-year. Gross profit increased by 50% to $11.7 million, with a gross margin of 62%. The company reiterated its full-year 2024 revenue guidance of at least $100 million and adjusted EBITDA of at least $11 million.

OptimizeRx reported Q1 2024 revenue of $19.7 million, a 51% increase year-over-year. Gross profit increased by 64% to $12.2 million, with a gross margin of 62%. The company won 9 DAAP deals during the quarter and reiterated its full-year 2024 revenue guidance of at least $100 million and Adjusted EBITDA of at least $11 million.

OptimizeRx expects revenue to increase over 40% year-over-year for Q1 2024, landing between $18.5 million and $19.2 million. The company anticipates a GAAP net loss and Adjusted EBITDA loss between $(8.2) - $(7.0) million and $(1.0) - $(0.7) million, respectively. The revenue increase was primarily driven by strong organic growth from DAAP and the acquisition of Medicx Health.

OptimizeRx reported strong third-quarter results, exceeding expectations due to the increased utilization of their Dynamic Audience Activation Platform (DAAP). The company's total DAAP deals for the year reached 16. They also completed the acquisition of Medicx Health after the quarter ended. The company increased its guidance for 2023 and introduced preliminary guidance for 2024.

OptimizeRx reported Q2 2023 financial results with a total revenue of $13.8 million. The company experienced a GAAP net loss per share of $(0.24) and a non-GAAP net loss per share of $(0.01). The RWD.AI-enabled portion of the core business saw 186% year-over-year growth during the first half of 2023.

OptimizeRx reported a solid start to 2023 with total revenue of $13.0 million. The company's execution remains on pace to meet its 2023 financial and operational objectives.

OptimizeRx reported its Q4 and full year 2022 financial results, highlighting the challenges faced due to macro headwinds and the strategic shift towards advanced solutions like RWD-AI. Despite a conservative outlook for 2023, the company sees positive momentum with several RWD-AI deals and anticipates a return to double-digit revenue growth.

OptimizeRx reported its Q3 2022 financial results, highlighting momentum in Real World Evidence (RWE) solutions. The company reiterated its full-year financial outlook for net revenue between $62 million and $68 million and gross margins between 59% and 62%.

OptimizeRx reported a 3% increase in revenue for Q2 2022, reaching $14.0 million, driven by growth in access solutions. The company experienced a net loss of $3.9 million, or $(0.21) per share, compared to a net income of $0.4 million in the same period last year. They are updating its full year financial outlook for 2022 and now expects net revenue of $62 million to $68 million.

OptimizeRx reported a 22% increase in revenue to $13.7 million for Q1 2022 compared to $11.2 million in Q1 2021. The company's gross margin increased to 59% from 55% in the year-ago quarter. The company reported a GAAP net loss of $3.8 million, or $(0.21) per share, compared to a net loss of $0.6 million, or $(0.04) per share in Q1 2021. Non-GAAP net loss was $0.1 million or $(0.01) per share compared to non-GAAP net income of $0.6 million or $0.04 per share in the same year-ago period.

OptimizeRx reported a 24% increase in Q4 revenue to $20.3 million compared to the same period in 2020. The company's gross margin increased to 61%. GAAP net income was $0.6 million, or $0.04 per basic share, while non-GAAP net income was $4.0 million, or $0.23 per basic share. OptimizeRx ended the quarter with $84.7 million in cash and cash equivalents.